Moberg Pharma completes tap issue of SEK 85m

STOCKHOLM, June 30, 2016. Moberg Pharma AB (OMX: MOB) has completed a tap issue of SEK 85 million to its outstanding bond loan (ISIN: SE0007953989). The proceeds will be used as part financing of the acquisition of New Skin®, Fiber Choice® and PediaCare® and for general corporate purposes.

The tap issue was made at a price of 100.50% of the nominal amount, indicating an interest rate of Stibor 3m + 5.88%. After the tap issue, the total outstanding amount of the Company’s bond loan amounts to SEK 385 million under a framework amount of SEK 600 million. The bond loan is listed on Nasdaq Stockholm and the Company will apply for listing of the new bonds on Nasdaq Stockholm. The settlement of the tap issue will occur on July 5, 2016. 

“We are pleased with the significant interest from Swedish and other Nordic investors. Our maintained activity in the corporate bond market strengthens our capacity to raise non-dilutive financing and we are very pleased to have been able to issue these subsequent bonds at a premium to the nominal amount, despite recent market turbulence”, said Peter Wolpert, CEO of Moberg Pharma AB.

Carnegie Investment Bank and Swedbank have acted as financial advisors and Gernandt & Danielsson as legal advisor in conjunction with the tap issue.

About this information               
Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 3.30 p.m. (CET) on June 30, 2016.

For additional information contact:                     
Peter Wolpert, CEO, Phone: +46 (0)70 - 735 7135, E-mail: peter.wolpert@mobergpharma.se    
Anna Ljung, CFO, Phone: +46 (0)70 - 766 60 30, E-mail: anna.ljung@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex® and Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Tags:

About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro® and Fiber Choice®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit: www.mobergpharma.com.

Contacts

Subscribe

Quotes

We are pleased with the significant interest from Swedish and other Nordic investors. Our maintained activity in the corporate bond market strengthens our capacity to raise non-dilutive financing and we are very pleased to have been able to issue these subsequent bonds at a premium to the nominal amount, despite recent market turbulence
Peter Wolpert, CEO of Moberg Pharma AB